Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications how zoonotic disease surveillance can influence evidence based policy decisions one
… worked as a Graduate Research Analyst for the Mississippi Evidence-based Drug Utilization Review (MS-DUR) Initiative at the … cardiovascular disorders, diabetes, inflammatory bowel disease, and cancer. She has worked with diverse data sources …
… surveys. These questions teach respondents how to interpret text and graphics and may help identify … but there was a wide range of results across the studies. Based on these results, we recommend a variety of approaches …
40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) Share on: Monday, May 9 - Friday, May 13, 2022 Conference Website Research coauthored by RTI Health Solutions researchers will be presented at the 40th Annual Meeting …
European Society for Paediatric Infectious Diseases (ESPID) 2023 Share on: Monday, May 8 - Friday, May 12, 2023 Conference website Research coauthored by RTI Health Solutions experts will be presented at ESPID 2023. Modelling the public health impact of …
… of health problems which include cancer, cardiovascular disease, neurologic disease, birth defects, injuries, environmental exposures, … or coauthored more than 450 peer-reviewed scholarly publications. He is a former president of the Society for …
… a brief, high-level explanation of your research topic and how this course would provide value to it. If you wish to … (GDPR) and RTI Health Solutions's data protection policy . …
… development is changing. Expedited regulatory approvals can help developers, but only if they are timely with … Our experience with these therapies includes several disease areas: Sickle cell disease Neuronal ceroid lipofuscinosis type 2 (CLN2) disease …
… (background information on patient population, burden of disease, comparators and their use); technical (description … and its characteristics); safety (safety of asset and how it compares to comparators); and clinical effectiveness. … It also means that the clinical efficacy and safety evidence submitted as part of the EMA regulatory dossier will …
… acknowledge the role patient-preference research can play in patient-focused drug development. The growing … interpretation, and use of patient preference information can support more inclusive and equitable health outcomes. …
… within regions. For example, in North America assessments can be as fast as 30 days, whilst in Asia assessments can be … plan their market access strategy and the associated evidence needs proactively and based on an understanding of regional HTA process. …